5/30
01:57 pm
blrx
BioLineRx stock jumps 14% on St. Jude clinical trial for mitoxafortide [Seeking Alpha]
Low
Report
BioLineRx stock jumps 14% on St. Jude clinical trial for mitoxafortide [Seeking Alpha]
5/30
07:08 am
blrx
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) [Yahoo! Finance]
High
Report
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) [Yahoo! Finance]
5/30
07:00 am
blrx
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
Medium
Report
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
5/29
10:55 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
BioLineRx Ltd. (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
5/28
07:20 am
blrx
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates [Yahoo! Finance]
Medium
Report
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates [Yahoo! Finance]
5/28
07:00 am
blrx
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
Low
Report
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
5/24
07:12 am
blrx
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting [Yahoo! Finance]
High
Report
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting [Yahoo! Finance]
5/24
07:00 am
blrx
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
High
Report
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
5/22
07:11 am
blrx
BioLineRx to Report First Quarter 2024 Results on May 28, 2024 [Yahoo! Finance]
Low
Report
BioLineRx to Report First Quarter 2024 Results on May 28, 2024 [Yahoo! Finance]
5/22
07:00 am
blrx
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
Low
Report
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
5/17
05:00 pm
blrx
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
Low
Report
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
5/6
07:00 am
blrx
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
Medium
Report
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
4/23
02:01 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) was upgraded by analysts at StockNews.com to a "sell" rating.
4/17
07:12 am
blrx
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting [Yahoo! Finance]
4/17
07:00 am
blrx
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
Low
Report
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
4/12
11:05 pm
blrx
BioLineRx Ltd. (NASDAQ: BLRX) was upgraded by analysts at StockNews.com to a "sell" rating.
High
Report
BioLineRx Ltd. (NASDAQ: BLRX) was upgraded by analysts at StockNews.com to a "sell" rating.
4/10
07:17 am
blrx
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement [Yahoo! Finance]
Low
Report
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement [Yahoo! Finance]
4/10
07:00 am
blrx
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
Low
Report
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
4/1
09:20 am
blrx
BioLineRx Announces $6 Million Registered Direct Offering [Yahoo! Finance]
Medium
Report
BioLineRx Announces $6 Million Registered Direct Offering [Yahoo! Finance]
4/1
09:00 am
blrx
BioLineRx Announces $6 Million Registered Direct Offering
High
Report
BioLineRx Announces $6 Million Registered Direct Offering
3/27
11:02 pm
blrx
BioLineRx Ltd. (NASDAQ: BLRX) was upgraded by analysts at StockNews.com to a "sell" rating.
Neutral
Report
BioLineRx Ltd. (NASDAQ: BLRX) was upgraded by analysts at StockNews.com to a "sell" rating.
3/27
12:28 pm
blrx
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/26
12:26 pm
blrx
BioLineRx Ltd. (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
3/26
07:17 am
blrx
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates [Yahoo! Finance]
High
Report
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates [Yahoo! Finance]
3/26
07:00 am
blrx
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
High
Report
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates